Other content in this Stream
Lisa Dilworth – VP of Operations for Parexel Biotech Americas West, and Sarah Glass – Global Head of Rare Diseases for Parexel, share candidly about their personal journeys with rare diseases and the
Biotech companies are the driving force behind the industry’s R&D pipeline as they develop and launch increasingly complex treatments. With more than 80% of the assets in development managed by...
Learn more from Roz Round, Parexel’s Vice President, Patient Innovation Center about how Decentralized Clinical Trials can help ensure patient safety and enable ongoing trial participation.
Parexel’s Anita Nelsen, SVP, Translational Medicine and Michelle Hoiseth, Chief Data Officer, Corporate VP speak with Ashley Druckenmiller about caring with her two sons with hemophilia and the benefi
Learn more about how to address operational challenges that come with harnessing RWD.
Amy McKee, Vice President Regulatory Consulting Services, addresses some of the most common misconceptions about working with the FDA.
Learn about the benefits that real-world evidence (RWE) can bring to small & mid-size biotech companies.
Enabling patients to participate in clinic trials from home is both important to maintain patient safety and data quality in ongoing trials and critical for many new trials as we plan for COVID-19.
In this blog, Parexel regulatory and strategy experts tackle the question of how we can ensure that worthy innovations in the biotech pipeline make it to patients sooner.
Learn more about what to look for in the right CRO partner to overcome logistical and operational challenges in cell and gene therapy product development.
Parexel precision medicine experts Angela Qu and Arlene Hughes join host Alberto Grignolo to discuss how biotech companies can incorporate precision medicine into their development plans.
Parexel’s Andreas Reiff, VP, Global TA Head, Inflammation/Immunology talks with Julie Stover, Senior Director, Solution Consulting, also from Parexel, about her journey being diagnosed with Ankylosing
Collectively, rare diseases affect over 30 million Americans. The Orphan Drug Act (ODA), which provides the statutory basis for FDA to designate a drug or biologic agent as a therapy for a...
The pharmaceutical industry is inundated with a plethora of communications about data integrity. Let's look at at one of these situations where applicant holders face these issues successfully.
Hear firsthand from Monica about her personal journey as a clinical trial participant to understand the value of easing patient burden